Trial · NCT02429427
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. | Celecoxib | 2 Year DFS rate | 91 | 95% Confidence Interval 90 to 93 | Percentage of participants |
| Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. | Placebo | 2 Year DFS rate | 90 | 95% Confidence Interval 87 to 92 | Percentage of participants |
| Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. | Celecoxib | 5 Year DFS rate | 84 | 95% Confidence Interval 82 to 86 | Percentage of participants |
| Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. | Placebo | 5 Year DFS rate | 83 | 95% Confidence Interval 81 to 86 | Percentage of participants |
| Overall Survival | Celecoxib | 2 Year | 97 | 95% Confidence Interval 96 to 97 | Percentage of participants |
| Overall Survival | Placebo | 2 Year | 96 | 95% Confidence Interval 95 to 97 | Percentage of participants |
| Overall Survival | Celecoxib | 5 Year | 90 | 95% Confidence Interval 89 to 92 | Percentage of participants |
| Overall Survival | Placebo | 5 Year | 91 | 95% Confidence Interval 88 to 92 | Percentage of participants |
| Number of Participants With Incidence of Second Primary Breast Cancers | Celecoxib | 19 | Participants | ||
| Number of Participants With Incidence of Second Primary Breast Cancers | Placebo | 12 | Participants | ||
| Cardiovascular Mortality | Celecoxib | 6 | Participants | ||
| Cardiovascular Mortality | Placebo | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02429427/results